- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01488409
Effects of Acipimox on Mitochondrial Function in Obesity
The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity
The purpose of the study is to examine whether a medication called acipimox can improve your body's mitochondria. Mitochondria are the "power house" of the cell and make energy for your body.
Obesity is associated with increased risk for developing diabetes. However, the investigators do not know how obesity leads to diabetes. Previous studies have shown levels of fat in the blood (free fatty acids or FFA) are higher in obesity, and elevated FFA can affect how our body uses glucose and responds to insulin. Recent studies have shown that changes in mitochondria may be involved in the development of diabetes and may be affected by FFA. The investigators propose to improve the function of mitochondria in obese people with pre-diabetes by treating with acipimox, a medication which decreases FFA. The investigators will use state of the art techniques to evaluate the mitochondria, including a new magnetic resonance imaging (MRI) technique to measure function of mitochondria in muscle.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women age 18-55 years old
- Body Mass Index (BMI) ≥ 30 kg/m2
- Waist circumference ≥ 102 cm in men and ≥ 88 cm in women
- Hypertriglyceridemia defined as triglycerides ≥ 150 mg/dl OR Insulin resistance defined as elevated fasting glucose (≥ 100 mg/dl but <125 mg/dl) or hyperinsulinemia defined as fasting serum insulin ≥ 10 uU/ml.
Exclusion Criteria:
- Subjects on any hormonal treatment including estrogen, hormone replacement therapy, oral contraceptives, testosterone, glucocorticoids, anabolic steroids, GH, GH releasing hormone or Insulin like growth factor (IGF)-1 within 3months of enrollment.
- Subjects who have a known history of diabetes, using any anti-diabetic drugs, or fasting blood glucose of ≥ 125 mg/dl.
- Use of cholesterol lowering medication including niacin or fish oil.
- Changes in anti-hypertensive regimen within 3months of screening.
- Chronic illness including HIV, anemia (Hgb <12 g/dL), chronic kidney disease (Creatinine > 2 mg/dL), or liver disease (SGOT > 2.5 x upper limit normal).
- Use of Aspirin, Clopidogrel (Plavix), Warfarin (Coumadin) or other anti-coagulants
- History of or active peptic ulcer disease
- History of any recent cardiovascular event including myocardial infarction (MI; heart attack), cerebral vascular accident (CVA; or stroke) or transient ischemic attack (TIA; or mini-stroke) within 3 months of screening visit, unstable angina pectoris, oxygen-dependent severe pulmonary disease
- Subjects with contraindication for an MRI study including any significant metal in their body including surgical clippings, or pacemakers and known claustrophobia.
- History of recent alcohol or substance abuse (< 1 year)
- Positive pregnancy test or lactating females
- Women of child-bearing potential not currently using non-hormonal birth control methods including barrier methods (intra-uterine device or IUD, condoms, diaphragms) or abstinence
- Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acipimox
Treatment with the study drug Acipimox
|
250 mg by mouth (PO) three times daily
|
Placebo Comparator: Placebo
Treatment with Placebo control.
|
0 mg by mouth (PO) three times daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Phosphocreatine Recovery (ViPCr) at 6-months
Time Frame: Change from Baseline to 6-months Visit
|
The rate of recovery of phosphocreatine concentration after depletion by exercise is considered a measurement of mitochondrial function.
Change in phosphocreatine recovery from baseline to 6 months will therefore give a measurement of change in mitochondrial function.
ViPCR is given -- a higher value indicates better mitochondrial function.
|
Change from Baseline to 6-months Visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Insulin Sensitivity at 6-months
Time Frame: Change from Baseline to 6-months visit
|
Change in insulin resistance assessed by hyperinsulinemic-euglycemic clamp study at Baseline and at 6-months.
Change in insulin-stimulated glucose uptake (M) during 40 mU/m2/min insulin clamp is given.
|
Change from Baseline to 6-months visit
|
Change From Baseline in Mitochondrial Density at 6 Months
Time Frame: Change from Baseline to 6-months
|
Muscle tissue obtained from biopsy will be used to assess mitochondrial number and morphology by microscopes at Baseline and at 6-months.
The change in mitochondrial density from 6 months to baseline is given.
|
Change from Baseline to 6-months
|
Change From Baseline in Intramyocellular Lipid Content at 6-months
Time Frame: Change from Baseline to 6-months
|
Change in tibialis intramyocellular lipid (IMCL) normalized to creatinine is given.
|
Change from Baseline to 6-months
|
Change From Baseline in Lipid Profile at 6-months
Time Frame: Change from Baseline to 6-months
|
Change in direct low density lipoprotein (LDL) cholesterol is given
|
Change from Baseline to 6-months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Hyperinsulinism
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Obesity
- Insulin Resistance
- Hypertriglyceridemia
- Obesity, Abdominal
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Hypolipidemic Agents
- Lipid Regulating Agents
- Acipimox
Other Study ID Numbers
- 2011-P-000175
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Resistance
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedEndoplasmic Reticulum Stress | HIV Related Insulin Resistance | Protease Inhibitor Related Insulin ResistanceUnited States
-
Paloma Almeda-ValdésCompleted
-
German Diabetes CenterYale UniversityRecruiting
-
National Institute of Diabetes and Digestive and...Active, not recruitingSevere Insulin ResistanceUnited States
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
Assiut UniversityCompleted
-
National Taiwan UniversityNational Cheng-Kung University HospitalCompletedExercise, Insulin Resistance, Visceral Adipose TissueTaiwan
-
The University of Texas Medical Branch, GalvestonCompletedInsulin Resistance, DiabetesUnited States
-
University Health Network, TorontoCompletedInsulin Resistance, DiabetesCanada
-
University Health Network, TorontoCompletedInsulin Resistance Syndrome X | Pancreatic Beta Cell FunctionCanada
Clinical Trials on Acipimox
-
University of AarhusCompletedHeart FailureDenmark
-
University of AarhusTerminated
-
Brigham and Women's HospitalCompletedMetabolic SyndromeUnited States
-
Medical University of ViennaCompleted
-
Maastricht University Medical CenterRecruiting
-
Brigham and Women's HospitalCompletedType 2 Diabetes MellitusUnited States
-
Charles University, Czech RepublicEnrolling by invitationBulimia Nervosa | Eating Disorder
-
University of AarhusCompletedObesity | DiabetesDenmark
-
Liverpool John Moores UniversityLiverpool University Hospitals NHS Foundation Trust; Royal Liverpool University... and other collaboratorsCompleted
-
The University of Texas Health Science Center at...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting